Skip to main content

Medicines labeled for the same conditions

Alternatives to tralokinumab

3 other medicines are given the same way (subcutaneous) and in the same FDA class as tralokinumab or labeled mainly for the same use (eczema (atopic dermatitis)); 1 is in its class, interleukin-13 antagonists: lebrikizumab; the others include 1 interleukin-4 receptor alpha antagonist and 1 interleukin-31 receptor alpha antagonist (FDA labels read October 8, 2026). In the same class, the lowest pharmacy cost is $1,783.52 per mL (Ebglyss 250 mg/2 mL pen) (what pharmacies paid in the NADAC survey; strengths differ).

Which medicines are labeled for the same conditions as tralokinumab?

Eczema (atopic dermatitis) lists all 26 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.

Medicine and FDA classShared indicationGeneric labelers (subcutaneous)Pharmacy costBoxed warningShortage
Tralokinumabinterleukin-13 antagonistthis medicinenone listedn/aNoNo current entry
Lebrikizumabinterleukin-13 antagonist · same classEczema (atopic dermatitis)none listed$1,783.52 per mL 250 mg/2 mL penNoNo current entry
Dupilumabinterleukin-4 receptor alpha antagonistEczema (atopic dermatitis)none listed$1,773.74 per mL 200 mg/1.14 mL syringNoNo current entry
Nemolizumabinterleukin-31 receptor alpha antagonistEczema (atopic dermatitis)none listedn/aNoNo current entry

Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)

What do pharmacies pay for each?

The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.

Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price

What next?

Tralokinumab: the full record
label, generics, price, shortages, recalls